Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 13/20 | 0.42 |
| ▸ | CA2 | P00918 | 13/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | YWHAG | P61981 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683308 | 0.80 | CA1 (0.47) | CA1CA2CA4METCA12 | |
| SCHEMBL6676148 | 0.79 | AKR1B10 (0.45) | CA1CA2ALOX5CA4MET | |
| SCHEMBL6679212 | 0.77 | LMNA (0.40) | CA1CA2ALOX5 | |
| SCHEMBL6676179 | 0.77 | LMNA (0.45) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13799682 | 0.77 | ERN1 (0.56) | CDK1 | |
| SCHEMBL27584202 | 0.75 | CA2 (0.64) | CA1CA2CA4CA12CA9 | |
| SCHEMBL28538352 | 0.71 | F2 (0.56) | CA1CA2CA4CA12CA9 | |
| SCHEMBL21693924 | 0.71 | APP (0.68) | ALOX5APPMETYWHAG | |
| SCHEMBL1936121 | 0.71 | LMNA (0.50) | CA1CA2ALOX5APPCA4 | |
| SCHEMBL1316310 | 0.71 | CDK1 (0.59) | CDK1ALOX5APPMETYWHAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |